share_log

6-K: Gsk Delivers Continued Strong Performance and Upgrades 2024 Guidance

6-K: Gsk Delivers Continued Strong Performance and Upgrades 2024 Guidance

GSK繼續保持強勁業績並上調​​2024年業績指引
美股SEC公告 ·  2024/08/01 00:31

Moomoo AI 已提取核心訊息

GSK delivered strong Q2 2024 performance with total sales of £7.9 billion, up 13% CER, driven by broad-based growth across all business areas. Core operating profit increased 18% to £2.5 billion, reflecting continued leverage from strong sales and favorable product mix. Core EPS grew 13% to 43.4p.The company upgraded its full-year 2024 guidance, now expecting sales growth of 7-9% (previously 5-7%), core operating profit growth of 11-13% (previously 9-11%), and core EPS growth of 10-12% (previously 8-10%). The improved outlook reflects strong commercial execution and strengthening portfolio breadth.R&D progress continued with positive data from key programs, including depemokimab for severe asthma and Blenrep in multiple myeloma. The company secured regulatory approvals and filings for 10 major opportunities and reported positive data from 7 phase III trials year-to-date, reinforcing confidence in future growth potential.
GSK delivered strong Q2 2024 performance with total sales of £7.9 billion, up 13% CER, driven by broad-based growth across all business areas. Core operating profit increased 18% to £2.5 billion, reflecting continued leverage from strong sales and favorable product mix. Core EPS grew 13% to 43.4p.The company upgraded its full-year 2024 guidance, now expecting sales growth of 7-9% (previously 5-7%), core operating profit growth of 11-13% (previously 9-11%), and core EPS growth of 10-12% (previously 8-10%). The improved outlook reflects strong commercial execution and strengthening portfolio breadth.R&D progress continued with positive data from key programs, including depemokimab for severe asthma and Blenrep in multiple myeloma. The company secured regulatory approvals and filings for 10 major opportunities and reported positive data from 7 phase III trials year-to-date, reinforcing confidence in future growth potential.
GSk在2024年第二季度的表現強勁，總銷售額達到79億英鎊，按固定匯率計算增長13%，這得益於所有業務領域的廣泛增長。核心營業利潤增長18%，達到25億英鎊，反映出強勁銷售和有利產品組合持續帶來的槓桿效應。核心每股收益增長13%，達到43.4便士。公司上調了2024年全年指引，現在預計銷售增長爲7-9%（此前爲5-7%），核心營業利潤增長爲11-13%（此前爲9-11%），核心每股收益增長爲10-12%（此前爲8-10%）。改善的前景反映出強大的商業執行力和不斷增強的產品組合廣度。研發進展持續向好，關鍵項目的積極數據包括針對重度哮喘的depemokimab和在多發性骨髓瘤中的Blenrep。公司獲得了10個重要機會的監管批准和備案，並報告了截至目前7個三期試驗的積極數據，這增強了對未來增長潛力的信心。
GSk在2024年第二季度的表現強勁，總銷售額達到79億英鎊，按固定匯率計算增長13%，這得益於所有業務領域的廣泛增長。核心營業利潤增長18%，達到25億英鎊，反映出強勁銷售和有利產品組合持續帶來的槓桿效應。核心每股收益增長13%，達到43.4便士。公司上調了2024年全年指引，現在預計銷售增長爲7-9%（此前爲5-7%），核心營業利潤增長爲11-13%（此前爲9-11%），核心每股收益增長爲10-12%（此前爲8-10%）。改善的前景反映出強大的商業執行力和不斷增強的產品組合廣度。研發進展持續向好，關鍵項目的積極數據包括針對重度哮喘的depemokimab和在多發性骨髓瘤中的Blenrep。公司獲得了10個重要機會的監管批准和備案，並報告了截至目前7個三期試驗的積極數據，這增強了對未來增長潛力的信心。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Medicus Pharma
    MDCX
    -- 3.680
    Scilex Holding
    SCLX
    -- 0.354
    阿瑪琳
    AMRN
    -- 0.612
    賽諾菲安萬特
    SNY
    -- 54.500
    艾伯維公司
    ABBV
    -- 192.870
    解鎖完整榜單
    熱門討論
    特朗普2.0時代開啟，全球市場將如何演變？
    🎙️討論： 1. 關稅政策將如何影響美股、黃金、比特幣等核心資產的走勢？ 2. 在此背景下，有哪些投資機會值得關注？你會如何佈局？ 展开
    MicroStrategy 2024年第4季度業績電話會
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。